Mediclinic International plc (Incorporated in England and Wales) Company Number: 08338604 LSE Share Code: MDC JSE Share Code: MEI NSX Share Code: MEP ISIN: GB00B8HX8Z88 LEI: 2138002S5BSBIZTD5I60 South African income tax number: 9432434182 ('Mediclinic', the 'Company', or the 'Group')

28 September 2022

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00B8HX8Z88

Issuer Name

MEDICLINIC INTERNATIONAL PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of voting rights

3. Details of person subject to the notification obligation

Name

JPMorgan Chase & Co.

City of registered office (if applicable)

Country of registered office (if applicable)

US

4. Details of the shareholder

Name	City of registered office	Country of registered office
J.P. Morgan Securities plc		

5. Date on which the threshold was crossed or reached

26-Sep-2022

6. Date on which Issuer notified

28-Sep-2022

7. Total positions of person(s) subject to the notification obligation

	% of voting rights attached to shares (total of 8.A)	% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)	Total of both in % (8.A + 8.B)	Total number of voting rights held in issuer
Resulting situation on the date on which threshold was crossed or reached	3.271379	1.756331	5.027710	37066786
Position of previous notification (if applicable)	Below minimum threshold	Below minimum threshold	Below minimum threshold	

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)	Number of direct voting rights (DTR5.1)	voting rights	% of direct voting rights (DTR5.1)	% of indirect voting rights (DTR5.2.1)
GB00B8HX8Z88		24118142		3.271379
Sub Total 8.A	24118142		3.271379	%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

	Type of financial instrument	 Exercise/conversion period	Number of voting rights that may be acquired if the instrument is exercised/converted	% of voting rights
Ī	Sub Total 8.B1			

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument	Expiration date	Exercise/conversion period	Physical or cash settlement	Number of voting rights	% of voting rights
Cash- settled Equity Swap	26/10/2022	26/10/2022	Cash	5474521	0.742564
Cash- settled Equity Swap	28/10/2022	28/10/2022	Cash	3241439	0.439669
Cash- settled	23/11/2022	23/11/2022	Cash	58635	0.007953

Equity Swap					
Cash- settled Equity Swap	01/02/2023	01/02/2023	Cash	16152	0.002190
Cash- settled Equity Swap	04/07/2023	04/07/2023	Cash	4119024	0.558694
Cash- settled Equity Swap	12/07/2023	12/07/2023	Cash	5065	0.000682
Cash- settled Equity Swap	09/08/2023	09/08/2023	Cash	759	0.000102
Cash- settled Equity Swap	18/08/2023	18/08/2023	Cash	145	0.000019
Cash- settled Equity Swap	22/08/2023	22/08/2023	Cash	598	0.000081
Cash- settled Equity Swap	06/09/2023	06/09/2023	Cash	8277	0.001122
Cash- settled Equity Swap	21/09/2023	21/09/2023	Cash	1588	0.000215
Cash- settled Equity Swap	03/10/2023	03/10/2023	Cash	5518	0.000747
Cash- settled	19/10/2023	19/10/2023	Cash	3768	0.000511

Equity Swap					
Cash- settled Equity Swap	27/10/2023	27/10/2023	Cash	647	0.000087
Cash- settled Equity Swap	12/02/2024	12/02/2024	Cash	11910	0.001615
Cash- settled Equity Swap	06/07/2027	06/07/2027	Cash	309	0.000041
Cash- settled Equity Swap	03/08/2027	03/08/2027	Cash	289	0.000039
Sub Total 8.B2			1	12948644	1.756331%

9. Information in relation to the person subject to the notification obligation

2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)

Ultimate controlling person	Name of controlled undertaking	% of voting rights if it equals or is higher than the notifiable threshold	% of voting rights through financial instruments if it equals or is higher than the notifiable threshold	equals or is higher than the notifiable
JPMorgan Chase & Co.	J.P. Morgan Securities plc			4.383003%
JPMorgan Chase & Co.	JPMorgan Chase Bank, National Association			
JPMorgan Chase & Co.	J.P. Morgan Equities South Africa Proprietary Limited			

JPMorgan J.P. Morgan Chase & Co. Securities LLC	
--	--

10. In case of proxy voting

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional Information

Chain of controlled undertakings:

JPMorgan Chase & Co.
JPMorgan Chase Bank, National Association (100%)
J.P. Morgan International Finance Limited (100%)
J.P. Morgan Capital Holdings Limited (100%)
J.P. Morgan Securities plc (100%)
JPMorgan Chase & Co.
JPMorgan Chase Bank, National Association (100%)

JPMorgan Chase & Co. JPMorgan Chase Bank, National Association (100%) J.P. Morgan International Finance Limited (100%) J.P. Morgan Capital Holdings Limited (100%) J.P. Morgan Equities South Africa Proprietary Limited (100%)

JPMorgan Chase & Co. JPMorgan Chase Holdings LLC (100%) J.P. Morgan Broker-Dealer Holdings Inc. (100%) J.P. Morgan Securities LLC (100%)

12. Date of Completion

28-Sep-2022

13. Place Of Completion

London

About Mediclinic International plc

Mediclinic is a diversified international private healthcare services group, established in South Africa in 1983, with divisions in Switzerland, Southern Africa (South Africa and Namibia) and the Middle East.

The Group's core purpose is to enhance the quality of life.

Its vision is to be the partner of choice that people trust for all their healthcare needs.

Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the continuum of care in such a way that the Group will be regarded as the most respected and trusted provider of healthcare services by patients, medical practitioners, funders and regulators of healthcare in each of its markets.

At 30 June 2022, Mediclinic comprised 74 hospitals, five subacute hospitals, two mental health facilities, 20 day case clinics and 23 outpatient clinics. The Swiss operations included 17 hospitals and four day case clinics with around 1 900 inpatient beds; Southern Africa operations included 50 hospitals (three of which in Namibia), five subacute hospitals, two mental health facilities and 14 day case clinics (four of which operated by Intercare) across South Africa, and around 8 650 inpatient beds; and the Middle East operated seven hospitals, two day case clinics and 23 outpatient clinics with around 1 000 inpatient beds in the UAE. In addition, under management contract the Middle East will open a 200-bed hospital in the Kingdom of Saudi Arabia in 2023.

The Company's primary listing is on the London Stock Exchange ("LSE") in the United Kingdom, with secondary listings on the JSE in South Africa and the Namibian Stock Exchange in Namibia.

Mediclinic also holds a 29.7% interest in Spire Healthcare Group plc, a leading private healthcare group based in the United Kingdom and listed on the LSE.

For further information, please contact:

Company Secretary, Link Company Matters Limited

Caroline Emmet +44 (0)333 300 1930

Investor Relations James Arnold, Head of Investor Relations ir@mediclinic.com +44 (0)20 3786 8181

Media queries

FTI Consulting Ben Atwell/Ciara Martin – United Kingdom +44 (0)20 3727 1000 Sherryn Schooling – South Africa +27 (0)21 487 9000

Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom **Website**: <u>www.mediclinic.com</u>

Corporate broker (United Kingdom): Morgan Stanley & Co International plc and UBS Investment Bank

JSE sponsor (South Africa): Rand Merchant Bank (A division of FirstRand Bank Limited) NSX sponsor (Namibia): Simonis Storm Securities (Pty) Ltd